期刊
JOURNAL OF HEPATOCELLULAR CARCINOMA
卷 8, 期 -, 页码 477-492出版社
DOVE MEDICAL PRESS LTD
DOI: 10.2147/JHC.S251729
关键词
hepatocellular carcinoma; HCC; regorafenib; tyrosine kinase inhibitor; TKI; systemic treatment; combination treatment
类别
Regorafenib has shown significant efficacy in the treatment of HCC, inhibiting tumor growth and spread while also positively impacting immunomodulation. Studies have confirmed its effectiveness as a second-line treatment after sorafenib failure.
Regorafenib was the first drug to demonstrate a survival benefit as a second-line agent after sorafenib failure in patients with unresectable hepatocellular carcinoma (HCC). Recent studies have shown that its mechanism of action is not only limited to its very broad spectrum of inhibition of angiogenesis, tumor proliferation, spread, and metastasis, but also to its immunomodulatory properties that have favorable effects on the very intricate role that the tumor microenvironment plays in carcinogenesis and tumor growth. In this review, we discuss rationale and evidence supporting regorafenib efficacy in HCC and that led to its approval as a second-line treatment, after sorafenib failure. We also discuss the evidence from clinical practice studies that confirm the results previously achieved in clinical trials. Finally, we analyze the potential role of regorafenib in emerging combined treatment approach with immunotherapy strategies using immune checkpoint blockade and its potential extension to patient categories not included in the registrative study.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据